Use of rosuvastatin in HIV-associated chronic obstructive pulmonary disease

AIDS

Volumn 31, Issue 4, 2017, Pages 539-544

  Morris, Alison ^a   Fitzpatrick, Meghan ^a   Bertolet, Marnie ^a   Qin, Shulin ^a   Kingsley, Lawrence ^b   Leo, Nicolas ^a   Kessinger, Cathy ^a   Michael, Heather ^a   McMahon, Deborah ^a   Weinman, Renee ^a   Stone, Stephen ^c   Leader, Joseph K ^a   Kleerup, Eric ^d   Huang, Laurence ^c   Wisniewski, Stephen R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chronic obstructive pulmonary disease; HIV; Inflammation; Lung; Statin

Indexed keywords

C REACTIVE PROTEIN; CARBON MONOXIDE; LIPID; PLACEBO; RITONAVIR; ROSUVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MALE; MIDDLE AGED; PHARMACEUTICAL CARE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; AGED; COMPLICATION; LUNG FUNCTION TEST; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; ROSUVASTATIN CALCIUM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85004008349     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001365     Document Type: Article

References (30)

1. Schwarcz SK, Vu A, Hsu LC, Hessol NA. Changes in causes of death among persons with AIDS: San Francisco, California, 1996-2011. AIDS Patient Care STDS 2014; 28:517-523.
2. Gingo MR, George MP, Kessinger CJ, Lucht L, Rissler B, Weinman R, et al. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med 2010; 182:790-796.
3. Morris A, Gingo MR, George MP, Lucht L, Kessinger C, Singh V, et al. Cardiopulmonary function in individuals with HIV infection in the antiretroviral therapy era. AIDS 2012; 26:731-740.
4. Drummond MB, Merlo CA, Astemborski J, Marshall MM, Kisalu A, McDyer JF, et al. The effect of HIV infection on longitudinal lung function decline among injection drug users: a prospective cohort. AIDS 2013; 27:1303-1311.
5. Samperiz G, Guerrero D, Lopez M, Valera JL, Iglesias A, Rios A, et al. Prevalence of and risk factors for pulmonary abnormalities in HIV-infected patients treated with antiretroviral therapy. HIV Med 2014; 15:321-329.
6. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
7. Drummond MB, Kirk GD, Ricketts EP, McCormack MC, Hague JC, McDyer JF, et al. Cross sectional analysis of respiratory symptoms in an injection drug user cohort: the impact of obstructive lung disease and HIV. BMC Pulm Med 2010; 10:27.
8. Crothers K, McGinnis K, Kleerup E, Wongtrakool C, Hoo GS, Kim J, et al. HIV Infection is associated with reduced pulmonary diffusing capacity. J Acquir Immune Defic Syndr 2013; 64: 271-278.
9. Fitzpatrick ME, Gingo MR, Kessinger C, Lucht L, Kleerup E, Greenblatt RM, et al. HIV infection is associated with diffusing capacity impairment in women. J Acquir Immune Defic Syndr 2016; 4:e12756.
10. Gingo MR, He J, Wittman C, Fuhrman C, Leader JK, Kessinger C, et al. Contributors to diffusion impairment in HIV-infected persons. Eur Respir J 2014; 43:195-203.
11. Crothers K, Petrache I, Wongtrakool C, Lee PJ, Schnapp LM, Gharib SA. Widespread activation of immunity and pro-inflammatory programs in peripheral blood leukocytes of HIVinfected patients with impaired lung gas exchange. Physiol Rep 2016; 4:.
12. Chakrabarti B, Calverley PM, Davies PD. Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2007; 2:263-272.
13. Brassard P, Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2010; 183:675-678.
14. Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J. Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction. Intern Med J 2005; 35:67-68.
15. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34:641-647.
16. Mihos CG, Artola RT, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review. Rheumatol Int 2012; 32:287-294.
17. Zeichner S, Mihos CG, Santana O. The pleiotropic effects and therapeutic potential of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in malignancies: a comprehensive review. J Cancer Res Ther 2012; 8:176-183.
18. Kim SE, Thanh Thuy TT, Lee JH, Ro JY, Bae YA, Kong Y, et al. Simvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extract. Exp Mol Med 2009; 41:277-287.
19. Lee SD, Lee JH, Kim EK, Choi KH, Oh YM, Shim TS. Effects of simvastatin on cigarette smoking-induced structural and functional changes in rat lungs. Chest 2005; 128:574S.
20. Criner GJ, Connett JE, Aaron SD, Albert RK, BaileyWC, Casaburi R, et al. Simvastatin for the prevention of exacerbations in moderate-to-severeCOPD.NEngl J Med 2014; 370:2201-2210.
21. Horita N, Miyazawa N, Kojima R, Inoue M, Ishigatsubo Y, Ueda A, et al. Statins reduce all-cause mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis of observational studies. Respir Res 2014; 15:80.
22. Ingebrigtsen TS, Marott JL, Nordestgaard BG, Lange P, Hallas J, Vestbo J. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax 2015; 70: 33-40.
23. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:2889-2934.
24. Ivanova A. A play-The-winner-type urn design with reduced variability. Metrika 2003; 58:1-13.
25. Barr JT, Schumacher GE, Freeman S, LeMoine M, Bakst AW, Jones PW. American translation, modification, and validation of the St. George's Respiratory Questionnaire. Clin Ther 2000; 22:1121-1145.
26. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26:720-735.
27. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005; 26:319-338.
28. Morris AM, Huang L, Bacchetti P, Turner J, Hopewell PC, Wallace JM, et al. Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. The Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 2000; 162:612-616.
29. Carlson AA, Smith EA, Reid DJ. The stats are in: an update on statin use in COPD. Int J Chron Obstruct Pulmon Dis 2015; 10:2277-2284.
30. Neukamm A, Hoiseth AD, Einvik G, Lehmann S, Hagve TA, Soyseth V, et al. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial. J Intern Med 2015; 278:59-67.